SBRT Combined With PD-1 Antibody and Chemotherapy in Oligometastatic Nasopharyngeal Carcinoma
Status:
Recruiting
Trial end date:
2025-09-01
Target enrollment:
Participant gender:
Summary
This is a multicenter, single-arm, phase II clinical trial. The purpose of this study is to
evaluate the efficacy and adverse effect of SBRT combined with programmed death 1 (PD-1)
antibody and chemotherapy in nasopharyngeal carcinoma patients with oligometastasis.
Phase:
Phase 2
Details
Lead Sponsor:
Sun Yat-sen University
Collaborators:
Chongqing University Cancer Hospital First People's Hospital of Foshan Jiangxi Provincial Cancer Hospital Shenzhen People's Hospital The First Affiliated Hospital of Xiamen University